United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

The U.S. Food and Drug Administration is aiming to grant full approval of the Pfizer-BioNTech coronavirus vaccine by Labor Day or sooner, according to a new report.

FDA aims for full approval of Pfizer COVID-19 vaccine by Labor Day: report

The pharmaceutical company filed its application with the FDA on May 7, and the FDA is expected to finish it's approval process by Labor Day weekend.

FDA expected to approve Pfizer-BioNTech's COVID-19 vaccine by early September: NYT

Inari Medical

Novavax

Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.

3 COVID Stocks That Could Soar Higher

Pfizer has produced extremely strong numbers this year.

Pfizer – Wind Beneath its Wings

New York City introduces a sweeping vaccination mandate, as authorities struggle to keep the coronavirus at bay.

Why Pfizer Shot 4% Higher Today

AbbVie

Gilead Sciences

GlaxoSmithKline

Walgreens

The healthcare sector is chock-full of safe, sturdy income plays. But these five top-rated high-yield dividend stocks really stand out in the crowd.

5 High-Yield Dividend Stocks for Healthy Income

Moderna

These elements may represent billions of dollars in the months and years to come.

3 Reasons Why Pfizer's and Moderna's Vaccine Revenue Growth Is Just Getting Started

AstraZeneca

Johnson & Johnson

It'll push the winners further ahead of the laggards.

How the Delta Variant Could Change the World of Coronavirus Vaccine Stocks

Pfizer might not have to wait very long for this product to hit the market.

This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine

Despite alarm around the spread of the Delta COVID variant, vaccine efficacy remains remarkably high. As a result, Moderna and Pfizer are.

Moderna And Pfizer Raise Vaccine Prices In Europe

Pfizer, Inc. (NYSE: PFE) and Moderna, Inc. (NASDAQ: MRNA), which have already minted billions of dollars from their respective COVID-19 vaccines, remain poised to earn more. What Happened: Pfizer and Moderna have both renegotiated their vaccine supply contract with the European Union, the FT reported Sunday.

Pfizer, Moderna Hike Prices Of Vaccine Shots Supplied To EU: Report

There is market concern about the emergence of the Delta variant of SARS-CoV-2. Delta is dangerous, but it looks containable with existing vaccines; the danger comes from new variants that are appearing.

Delta Variant And The Markets

Merck

Can Merck Beat Pfizer in This Multibillion-Dollar Vaccine Market?

Innovative Industrial Properties

NextEra Energy

It doesn't take much money -- or a lot of time, really -- to make $1 million.

Investing in These Stocks Now Could Make You a Millionaire Retiree

Data and the vaccination timeline support the idea of a new jab now.

4 Words from Pfizer's CEO That May Mean a Booster Is Imminent

Align Technology

Guardant Health Inc

Nano-X Imaging

There's both rhyme and reason for checking out these four stocks.

Missed Out on the FAANG Stocks? Consider Buying These PfANG Stocks Instead.

The firms are already taking the lion's share of earnings from the market, as this week's results will show

As Delta spreads, Pfizer and Moderna get set for a booster shot to profits

Hint: You may have heard a lot about this company in the past year.

Amid the Rise of the Delta Variant, Here's My Top Coronavirus Vaccine Stock to Buy

What Would Full FDA Approval of Pfizer's COVID Vaccine Mean for the Stock?

These two companies offer impressive -- and safe -- yields for investors who like income.

Have $500? Here Are 2 High-Yielding Healthcare Stocks to Consider

Pfizer is ready to take on a second coronavirus market.

This 1 Thing in Pfizer's Earnings Report May be a Coronavirus Game Changer

Israeli health officials said they've seen protection against severe illness from Pfizer's vaccine decrease from 97% to 81% over time.

Israel will roll out a booster dose of the Pfizer-BioNTech COVID-19 vaccine to older people, citing a drop in protection against severe disease driven by the Delta variant

In Q2, Pfizer's revenue increased 93% year-over-year. The midpoint of guidance for 2021 results in 85% revenue growth over 2020.

Why Pfizer Is One Of My Largest Positions

Today AstraZeneca plc (NASDAQ: AZN) released its second-quarter earnings with updated sales numbers for its COVID-19 vaccine; when compared to the big mRNA players, the numbers looked rather pale. Q2 Sales Numbers: AstraZeneca's COVID-19 jab clocked in about $1.17 billion globally in the first half, including $894 million in the second quarter alone.

Cashing COVID-19 Vaccine - AstraZeneca Or Pfizer

The effectiveness of Pfizer's COVID-19 shot can drop to 83% within four to six months after getting the second dose of its vaccine. This is the latest indication that vaccine-induced immunity to the virus can wane and some kind of boost may be necessary in the future.

News for Pfizer Stock (PFE)